MPZL1 is highly expressed in advanced gallbladder carcinoma and promotes the aggressive behavior of human gallbladder carcinoma GBC‑SD cells

Liu,Xiaolei; Huang,Jia; Liu,Liguo; Liu,Rong

doi:10.3892/mmr.2019.10506

MPZL1 is highly expressed in advanced gallbladder carcinoma and promotes the aggressive behavior of human gallbladder carcinoma GBC‑SD cells

Authors:
- Xiaolei Liu
- Jia Huang
- Liguo Liu
- Rong Liu
View Affiliations

Affiliations: Department of Hepato‑Pancreato‑Biliary Surgical Oncology, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of General Surgery, China‑Japan Friendship Hospital, Beijing 100029, P.R. China
Published online on: July 18, 2019 https://doi.org/10.3892/mmr.2019.10506
Pages: 2725-2733
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myelin protein 0‑like 1 (MPZL1) has been reported to have a role in hepatocellular carcinoma. However, to the best of our knowledge, there have been no studies on the function and molecular mechanism of MPZL1 gene in gallbladder carcinoma. The present study confirmed that MPZL1 was upregulated in four gallbladder carcinoma tissues according to the mRNA microarray analysis. The results of the immunohistochemical analysis of tissues from 82 patients with gallbladder carcinoma demonstrated that patients with advanced tumor stages (both T and N stage) had higher positive expression of MPZL1. Moreover, a total of 20 cases of gallbladder carcinoma and matched paired paracarcinoma tissues along with 20 samples of healthy gallbladder tissue from patients with cholecystitis were analyzed using reverse transcription‑quantitative PCR and western blotting. The results demonstrated that the expression of MPZL1 in gallbladder carcinoma tissues was significantly higher than that of paired paracarcinoma tissues and randomly matched normal gallbladder epithelial tissues. According to the Tumor‑Node‑Metastasis classification, the expression level of MPZL1 protein in stage IV gallbladder carcinoma was significantly higher than that in stage III gallbladder carcinoma. The enhanced expression of MPZL1 gene appeared to improve the migration ability of GBC‑SD cells. Conversely, GBC‑SD cells that transfected with MPZL1 siRNA exhibited decreased migration ability. The results of proliferation experiments showed that the knockdown of MPZL1 siRNA caused impairments in GBC‑SD cell proliferation. On the contrary, the overexpression of MPZL1 increased the proliferation ability of GBC‑SD cells. The results of flow cytometry analyses indicated that the upregulation of MPZL1 had an anti‑apoptotic effect on GBC‑SD cells. In conclusion, the present study showed that the expression and protein levels of MPZL1 were significantly higher in gallbladder carcinoma tissues, especially in patients diagnosed with advanced tumor stages. Overexpression of MPZL1 may have promoted the invasion, metastasis, proliferation and survival of GBC‑SD cells.

View Figures

View References

1	Bizama C, García P, Espinoza JA, Weber H, Leal P, Nervi B and Roa JC: Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev. 41:222–234. 2015. View Article : Google Scholar : PubMed/NCBI
2	Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S and La Vecchia C: Epidemiology of biliary tract cancers: An update. Ann Oncol. 20:146–155. 2009. View Article : Google Scholar : PubMed/NCBI
3	Goetze TO: Gallbladder carcinoma: Prognostic factors and therapeutic options. World J Gastroenterol. 21:12211–12217. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hundal R and Shaffer EA: Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol. 6:99–109. 2014.PubMed/NCBI
5	Yeh YT, Dai HY and Chien CY: Amplification of MPZL1/PZR gene in hepatocellular carcinoma. Hepatobiliary Surg Nutr. 3:87–90. 2014.PubMed/NCBI
6	Zhao ZJ and Zhao R: Purification and cloning of PZR, a binding protein and putative physiological substrate of tyrosine phosphatase SHP-2. J Biol Chem. 273:29367–29372. 1998. View Article : Google Scholar : PubMed/NCBI
7	Taniguchi K and Karin M: IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 26:54–74. 2014. View Article : Google Scholar : PubMed/NCBI
8	Zannettino AC, Roubelakis M, Welldon KJ, Jackson DE, Simmons PJ, Bendall LJ, Henniker A, Harrison KL, Niutta S, Bradstock KF and Watt SM: Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: Identification, molecular cloning and effects on cell migration. Biochem J. 370:537–549. 2003. View Article : Google Scholar : PubMed/NCBI
9	Zhang J, Zhang F and Niu R: Functions of Shp2 in cancer. J Cell Mol Med. 19:2075–2083. 2015. View Article : Google Scholar : PubMed/NCBI
10	Labbé DP, Hardy S and Tremblay ML: Protein tyrosine phosphatases in cancer. Friends and foes! Prog Mol Biol Transl Sci. 106:253–306. 2012. View Article : Google Scholar : PubMed/NCBI
11	Huang WQ, Lin Q, Zhuang X, Cai LL, Ruan RS, Lu ZX and Tzeng CM: Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis. Curr Cancer Drug Targets. 14:567–588. 2014. View Article : Google Scholar : PubMed/NCBI
12	Chan G, Kalaitzidis D and Neel BG: The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27:179–192. 2008. View Article : Google Scholar : PubMed/NCBI
13	Grossmann KS, Rosário M, Birchmeier C and Birchmeier W: The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res. 106:53–89. 2010. View Article : Google Scholar : PubMed/NCBI
14	Roubelakis MG, Martin-Rendon E, Tsaknakis G, Stavropoulos A and Watt SM: The murine ortholog of the SHP-2 binding molecule, PZR accelerates cell migration on fibronectin and is expressed in early embryo formation. J Cell Biochem. 102:955–969. 2007. View Article : Google Scholar : PubMed/NCBI
15	Seda Eminaga and Anton M: Bennett: Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPα and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation. J Biol Chem. 283:15328–15338. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kusano K, Thomas TN and Fujiwara K: Phosphorylation and localization of protein-zero related (PZR) in cultured endothelial cells. Endothelium. 15:127–136. 2008. View Article : Google Scholar : PubMed/NCBI
17	Jia D, Jing Y, Zhang Z, Liu L, Ding J, Zhao F, Ge C, Wang Q, Chen T, Yao M, et al: Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Res. 24:204–217. 2014. View Article : Google Scholar : PubMed/NCBI
18	Yu T, Liang L, Zhao X and Yin Y: Structural and biochemical studies of the extracellular domain of Myelin protein zero-like protein 1. Biochem Biophys Res Commun. 506:883–890. 2018. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Ma MZ, Kong X, Weng MZ, Zhang MD, Qin YY, Gong W, Zhang WJ and Quan ZW: Long non-coding RNA-LET is a positive prognostic factor and exhibits tumor-suppressive activity in gallbladder cancer. Mol Carcinog. 54:1397–1406. 2015. View Article : Google Scholar : PubMed/NCBI
21	Caplen NJ, Parrish S, Imani F, Fire A and Morgan RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 98:9742–9747. 2001. View Article : Google Scholar : PubMed/NCBI
22	Yoon HA, Noh MH, Kim BG, Han JS, Jang JS, Choi SR, Jeong JS and Chun JH: Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol. 17:4023–4030. 2011. View Article : Google Scholar : PubMed/NCBI
23	Bao RF, Shu YJ, Hu YP, Wang XA, Zhang F, Liang HB, Ye YY, Li HF, Xiang SS, Weng H, et al: miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma. Oncotarget. 7:22339–22354. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zhang P, Guo Z, Wu Y, Hu R, Du J, He X, Jiao X and Zhu X: Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling. PLoS One. 10:e01361932015. View Article : Google Scholar : PubMed/NCBI
25	Xie F, Xu X, Xu A, Liu C, Liang F, Xue M and Bai L: Aberrant activation of Sonic hedgehog signaling in chronic cholecystitis and gallbladder carcinoma. Hum Pathol. 45:513–521. 2014. View Article : Google Scholar : PubMed/NCBI
26	Hunter T: Tyrosine phosphorylation: Thirty years and counting. Curr Opin Cell Biol. 21:140–146. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hunter T: Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell. 80:225–236. 1995. View Article : Google Scholar : PubMed/NCBI
28	Krause DS and Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med. 353:172–187. 2005. View Article : Google Scholar : PubMed/NCBI
29	Zhao S, Sedwick D and Wang Z: Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene. 34:3885–3894. 2015. View Article : Google Scholar : PubMed/NCBI
30	Gaumann AK, Kiefer F, Alfer J, Lang SA, Geissler EK and Breier G: Receptor tyrosine kinase inhibitors: Are they Real Tumor Killers? Int J Cancer. 138:540–554. 2016. View Article : Google Scholar : PubMed/NCBI
31	Tonks NK: Protein tyrosine phosphatases-from housekeeping enzymes to master regulators of signal transduction. FEBS J. 280:346–378. 2013. View Article : Google Scholar : PubMed/NCBI
32	Julien SG, Dubé N, Hardy S and Tremblay ML: Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 11:35–49. 2011. View Article : Google Scholar : PubMed/NCBI
33	He RJ, Yu ZH, Zhang RY and Zhang ZY: Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin. 35:1227–1246. 2014. View Article : Google Scholar : PubMed/NCBI
34	Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, Liu C, Shen B, Wang XA, Wu W, et al: Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 46:872–876. 2014. View Article : Google Scholar : PubMed/NCBI
35	Zhao R, Fu X, Teng L, Li Q and Zhao ZJ: Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains. J Biol Chem. 278:42893–42898. 2003. View Article : Google Scholar : PubMed/NCBI
36	Eminaga S and Bennett AM: Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation. J Biol Chem. 283:15328–15338. 2008. View Article : Google Scholar : PubMed/NCBI
37	Chen L, Wang ZW, Zhu JW and Zhan X: Roles of cortactin, an actin polymerization mediator, in cell endocytosis. Acta Biochim Biophys Sin (Shanghai). 38:95–103. 2006. View Article : Google Scholar : PubMed/NCBI
38	Sung BH, Zhu X, Kaverina I and Weaver AM: Cortactin controls cell motility and lamellipodial dynamics by regulating ECM secretion. Curr Biol. 21:1460–1469. 2011. View Article : Google Scholar : PubMed/NCBI
39	Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L and Yang J: Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 19:372–386. 2011. View Article : Google Scholar : PubMed/NCBI
40	Zhao R, Guerrah A, Tang H and Zhao ZJ: Cell surface glycoprotein PZR is a major mediator of concanavalin A-induced cell signaling. J Biol Chem. 277:7882–7888. 2002. View Article : Google Scholar : PubMed/NCBI